rethinkPeptides Search
Menu
Study breakdown

A New Peptide Carrier That Delivers Enzymes to Lysosomes for Treating Storage Diseases

In Vitro (Proof Of Concept)Preliminary evidence
The takeaway

A fusion peptide combining polylysine and polyhistidine successfully delivers replacement enzymes to lysosomes, restoring normal cell growth in lysosomal storage disease cells.

Restored growth

LSD cells treated with K10H16-delivered enzyme resumed normal proliferation rates

What the researchers found

The K10H16 fusion peptide delivers functional enzymes to intracellular lysosomes via electrostatic complexation, restoring normal cell growth in lysosomal storage disease cells.

Why it matters

Lysosomal storage diseases currently require enzyme replacement therapy with limited cell penetration. A peptide carrier delivering enzymes directly to lysosomes could dramatically improve treatment efficacy.

The numbers in context

K10H16 (26 AA); lysosomal targeting confirmed; GLA delivered; LSD cell proliferation restored; simple electrostatic mixing

How the study worked

Peptide synthesis, fluorescent protein delivery tracking, alpha-galactosidase A delivery to LSD cells, and cell proliferation assays.

Who was studied

Lysosomal storage disease cell model; HeLa cells

What this study cannot tell us

In vitro proof-of-concept only. No in vivo data on peptide stability, biodistribution, or therapeutic efficacy.

How to read the evidence

In vitro proof-of-concept demonstrating peptide-mediated enzyme delivery to lysosomes. Promising but requires in vivo validation.

When this study was published

Published in 2020. The concept of CPP-mediated enzyme delivery continues to be actively explored.

The bigger picture

This approach could transform enzyme replacement therapy for lysosomal storage diseases by solving the fundamental challenge of getting replacement enzymes inside cells to the organelle where they're needed.

Questions still open

  • Does K10H16 work for delivering enzymes in animal models of lysosomal storage diseases?
  • Can this approach be adapted for other lysosomal enzyme deficiencies beyond Fabry disease?
  • How does efficiency compare to existing enzyme replacement approaches?

Common questions

What are lysosomal storage diseases?
Lysosomal storage diseases are genetic conditions where cells lack specific enzymes needed to break down waste products inside lysosomes (cellular recycling centers). Without these enzymes, waste accumulates and causes cell damage. There are over 50 types, including Fabry disease.
How does this peptide deliver enzymes into cells?
The K10H16 peptide has two functional parts: a positively charged polylysine section that binds to negatively charged enzymes, and a polyhistidine section that enables cell entry. Once inside the cell, the peptide-enzyme complex is directed to lysosomes where the enzyme is needed.

Read the original research

A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.

Biochemical and biophysical research communications, 533(4), 905-912

Citation

Iwasaki, Takashi; Murakami, Nodoka; Kawano, Tsuyoshi. (2020). A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.. Biochemical and biophysical research communications, 533(4), 905-912. https://doi.org/10.1016/j.bbrc.2020.09.087